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Single nucleotide variant mappingThe number of blood group systems, currently 35, has increased in the recent years as genetic variations deﬁning
red cell antigens continue to be discovered. At present, 44 genes and 1568 alleles have been deﬁned as encoding
antigens within the 35 blood group systems. This paper provides a brief overview of two genetic technologies:
single nucleotide variant (SNV) mapping by DNA microarray and massively parallel sequencing, with respect
to blood group genotyping. The most frequent genetic change associated with blood group antigens are SNVs.
To predict blood group antigen phenotypes, SNV mapping which involves highly multiplexed genotyping, can
be performed on commercial microarray platforms. Microarrays detect only known SNVs, therefore, to type
rare or novel alleles not represented in the array, further Sanger sequencing of the region is often required to
resolve genotype. An example discussed in this article is the identiﬁcation of rare and novel RHD alleles in the
Australian population. Massively parallel sequencing, also known as next generation sequencing, has a high-
throughput capacity and maps all points of variation from a reference sequence, allowing for identiﬁcation of
novel SNVs. Examples of the application of this technology to resolve the genetic basis of orphan blood group
antigens are presented here. Overall, the determination of a full proﬁle of blood group SNVs, in addition to sero-
logical phenotyping, provides a basis for provision of compatible blood thus offering improved transfusion safety.
© 2014 McBean et al. Published by Elsevier B.V. on behalf of the Research Network of Computational and
Structural Biotechnology. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Contents1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
2. Preparation of sample material for molecular methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
3. SNV mapping by DNA microarrays . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
3.1. Overview of technology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
3.2. Advantages . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
3.3. Limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
3.4. Applications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
3.5. Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
4. Massively parallel sequencing to deﬁne a blood group phenotype . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
4.1. Overview of technology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
4.2. Advantages . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
4.3. Limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
4.4. Applications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
4.5. Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
5. Summary and outlook . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150boratory, AustralianRed Cross Blood Service, 44Musk Avenue, Kelvin Grove, Queensland4059, Australia. Tel.:+61 7 3838 9372;
cBean).
. on behalf of the Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY
148 R.S. McBean et al. / Computational and Structural Biotechnology Journal 11 (2014) 147–1511. Introduction
Blood group systems are comprised of red cell surface antigens
(proteins, glycoproteins or glycolipids) which are deﬁned by a human
alloantibody [1]. Blood group systems are inherited and controlled by
a single gene or cluster of two or three closely-linked homologous
genes [1]. The number of blood group systemsmeeting the classiﬁcation
requirements of the International Society for Blood Transfusion, cur-
rently 35, has increased in the recent years as genetic variationsdeﬁning
red cell antigens continue to bediscovered. At present, 44 genes that en-
code the 35 blood group systems have been identiﬁedwith 1568 alleles
listed in the NCBI Blood Group Gene Mutation Database [2]. The most
frequent genetic change determining blood type is single nucleotide
variation (SNV) resulting in a missense mutation. Inactivating muta-
tions such as deletions and splice-site mutations also result in new epi-
topes or loss of a red cell surface protein. Additionally, crossover events
between closely-linked homologous genes, such as RHD and RHCE or
GYPA and GYPB, create hybrid alleles often resulting in the expression
of partial antigens and/or neo antigens [3,4].
Traditionally the presence, or absence, of a blood group antigen has
been determined by phenotyping using antibody-based serological
methods. Genotyping of SNVs encoding blood group antigens provides
a prediction of phenotype and the application of genotyping methods
to blood group typing is a powerful tool to complement, and to over-
come some of the limitations of, serology [5–7]. Genotyping can im-
prove the accuracy of typing in cases where serology alone is unable
to resolve red cell phenotype, for example in individuals who have
weakened antigen expression due to the presence of genetic variants.
Furthermore, there are scenarios in which genotyping is the only meth-
od available for typing of blood group antigens, such as cases of rare
phenotypes where antisera are unavailable [8–10]; in recently- or
multi-transfused patients [11,12]; and for the determination of blood
type of a fetus via genotyping of cell free fetal DNA in maternal plasma
[13,14]. Additionally, genotyping with multiplex or parallel reactions
in a single assay is more feasible than serological typing for large-scale
population screening studies.
Blood group genotyping by in-house PCR-based assays, either for a
single or small number of SNVs, has been undertaken by specialized lab-
oratories since the 1990's. Thesemethods have included PCR-restriction
fragment length polymorphism (RFLP), sequence-speciﬁc primer
(SSP)-PCR, single-nucleotide primer extension, and more recently,
real-time (RT)-PCR and high resolution melt (HRM) analyses [15–18].
Although these assays have proven to be accurate, they are limited by
their low-throughput, limited multiplex capacity, and the number of
manual steps involved. In the 21st century, microarray-based genotyp-
ing platforms were developed to overcome these limitations. Discussed
in this review are the BloodChip Reference from Progenika (Grifols) and
the BeadChip from BioArray Solutions (Immucor), which were among
the ﬁrst to be developed and achieve regulatory accreditation. In more
recent times, commercially available SNV typing platforms based on
technologies capable of even higher throughput, including Luminex
xMAP and single nucleotide primer extension followed by matrix-
assisted laser desorption/ionization time-of-ﬂight mass spectrometry
(MALDI-TOF MS), have become available [19,20].
As we progress into the 21st century, massively parallel sequencing
(MPS), or next generation sequencing, has emerged as a result of the
Human Genome Project and later full genome assemblies for other spe-
cies [21–23]. This technology can be applied to sequencing the whole
genome, the exome, or a panel of selected genes, andwith cost decreas-
ing; this technology is being applied in medical diagnostics research
[24].
This review is designed to overview two approaches to blood group
genotyping, microarray-based genotyping, focusing on two available
genotyping platforms, and MPS. This review provides an overview of
these technologies as well as the advantages, limitations and examples
of the recent applications. It is recognized there are numerousmicroarrays and MPS platforms available, however, a detailed compar-
ison of these platforms is outside the scope of this review.
2. Preparation of sample material for molecular methods
Irrespective of the molecular approach utilized, genomic DNA
extracted without the risk of contamination from the external environ-
ment is required as the input material. For minimisation of contamina-
tion and for optimisation of workﬂow, it is preferred that DNA
extraction is performed in an automated and high-throughput fashion.
Vendors of commercially available DNA extraction platforms vary be-
tween jurisdictions; however, the robustness of these platforms is
well-accepted. One current limitation of all available genotyping and se-
quencing platforms is that theDNAextraction step is not integrated into
a fully automated process. Thus, DNA extraction remains an indepen-
dent step performed prior to molecular investigations.
3. SNV mapping by DNA microarrays
3.1. Overview of technology
SNV mapping to predict blood group antigens is most commonly
performed by DNA microarrays. DNA microarrays can be deﬁned as
miniaturized solid surface assays of high multiplexing power [25]. The
solid surface of a DNA microarray commonly consists of a chip, wafer
or bead, with probes corresponding to various blood group alleles
bound to the surface. During the microarray process, allele-speciﬁc hy-
bridization occurs between complementary probes and labeled DNA
fragments from a sample, and this is measured to determine genotype.
There are several commercial DNA microarray platforms currently
available for blood group genotyping. In this paper we discuss two
widely utilized platforms for blood group genotyping, the BloodChip
Reference from Progenika (Grifols) and the BeadChip from BioArray
Solutions (Immucor). Other available platforms include LIFECODES
RBC/RBC-R (Gen-Probe) and ID CORE XT (Progenika) based on Luminex
technology [26], GenomeLab SNP stream(Beckman) [27], theHIFI Blood
96 (AXO Science) [28] and the Hemo ID Blood Group Genotyping Panel
(Agena Bioscience) [20]. Comprehensive reviews on currently available
SNV typing platforms are provided by Veldhuisen et al. and Boccoz et al.
[29,30].
The BloodChip Reference was developed between 2003 and 2006 by
the Bloodgen project funded by the European Commission [31].
Genotyping by the BloodChip Reference platform involves multiplex
PCR ampliﬁcation, labeling of the ampliﬁed products and hybridisation
to allele-speciﬁc probes on a glass slide [31]. A laser array scanner is
used to detect binding at each probe location and software determines
the genotype and predicted phenotype by comparing the strength of
binding of the labeled PCR products to probes [31]. The BloodChip Ref-
erence assay genotypes up to 24 samples in ten hours. The BloodChip
Reference microarray contains approximately 6280 spots with 256 in-
ternal controls and 40 replicates per allele. The BloodChip Reference
v4.1 genotypes 128 SNVs for 33 clinically signiﬁcant antigens from the
ABO, RH, KEL, FY, DO, CO, LU, DI, JK and MNS blood group systems.
The desire to predict RHD variants was a major focus of the BloodChip
Reference design and the number of RHD alleles incorporated in the
BloodChip assay is extensive [31–33].
The HEA BeadChip was developed and validated by BioArray Solu-
tions and the New York Blood Centre and became commercially avail-
able in 2006 [34,35]. Genotyping by BeadChip involves multiplex PCR
ampliﬁcation of DNA followed by denaturation and hybridization to
color-coded beads incorporating allele-speciﬁc probes with variable 3′
ends [34].When binding occurs between a complementary PCRproduct
and probe, the probe elongates, producing a ﬂuorescent signal [34]. An
image is taken with an automated Array Imaging System and the ﬂuo-
rescent signal intensities determined and correlated with the corre-
sponding probes to provide the basis for genotype and predicted
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hours. The BeadChip microarray contains approximately 4000 beads
comprising seven negative and positive reaction controls and 25 to 40
replicates per allele. Different BeadChip modules are available, with a
focus on the range of blood group SNVs to be tested. The human eryth-
rocyte antigen (HEA) BeadChip genotypes 24 alleles encoding 38 anti-
gens from the RHCE, KEL, FY, DO, LW, CO, SC, LU, DI, JK and MNS blood
group systems. Additional chips are available (RHD BeadChip and
RHCE BeadChip) for targeted red cell genotyping [35].
3.2. Advantages
Genotyping blood group SNVs using microarray technology has
many advantages over traditional serological or basic in-house PCR-
based tests. Microarrays test for multiple markers simultaneously, pro-
viding in-depth information on one blood group system or many blood
group systems, depending on the module utilized. Microarrays have a
proven track-record for sensitivity and speciﬁcity and some platforms,
including BloodChip Reference andHEA BeadChip, have obtained Coun-
cil of Europe marking (accreditation as suitable for use in a diagnostic
environment). Furthermore, microarray data analysis software allows
rapid interpretation of the signals generated by binding of probes and
DNA fragments into an easily understood genotype and predicted phe-
notype. These automated microarray data analysis processes offer sig-
niﬁcant advantages over traditional serological and in-house PCR-
based tests. This is because for traditional methods, analysis of data is
often amoremanual and time consuming process and can be subjective
or open to interpretation, for example the scoring of red cell agglutina-
tion by eye.
3.3. Limitations
The most obvious limitation of all SNV microarray platforms is that
they utilize a targeted genotyping approach and thus genotype only al-
leles incorporated in themicroarray.Most platforms areﬁxed and adap-
tation, once new alleles are discovered, requires time for speciﬁc design
and validation, and is at the discretion of the manufacturer rather than
the user.
In a small number of cases, genotype does not accurately reﬂect phe-
notype. For example, microarray platforms may provide an inaccurate
prediction due to the presence of a silencing SNV located outside of
the targeted area. In these cases the genotyping platform will detect
an apparently normal allele inconsistent with serological results [36,
37]. In this area, further design improvements may be required as new
variants are reported.
It must also be considered that commercially available platforms
may be designed for a speciﬁc population. For example the BloodChip
Reference was designed for SNVs within the European population
whereas the BeadChip was designed with the American population
with African-American SNVs in the DO blood group system and RHCE
gene as a focus. In Australia, we have a varied and multi-ethnic popula-
tion with a large proportion of individuals of Asian ancestry who may
carry alleles in theMNS blood group system and RHD gene, not incorpo-
rated in these genotyping platforms.
3.4. Applications
Interestingly, few studies have performed direct comparison of com-
mercially available genotyping platforms. Recently in our laboratory
we undertook a study involving genotyping of reagent red blood cell
donors utilizing three commercially available microarray platforms. Re-
agent red blood cell donors are extensively serologically phenotyped
and it is critical that these phenotypes are accurate. Comparative analy-
sis of commercial SNV typing platforms, including BloodChip Reference
and BeadChip, provided evidence that each platform produces reliable
data. In this study, sensitivity and speciﬁcity of 100% were achieved byeach platform on the sample set tested (n=196) [38]. A phenotype ge-
notype discrepancy rate of 10.4% was detected and discrepancies iden-
tiﬁed were in clinically signiﬁcant blood group systems [38]. All
discrepancies were in samples presumed to be homozygous for antigen
expression based on serological typing, however genotyping detected
mutations encoding for weakened antigen expression. Overall, this
study highlighted the utility of genotyping, speciﬁcally for the detection
of SNVswhich encode forweakened antigen expression of clinically sig-
niﬁcant blood groups, speciﬁcally RhD and Fyb antigen expression.
The Rh blood group system is highly polymorphic, as demonstrated
by Wagner et al. [39,40]. Both the strengths and limitations of SNV-
based genotyping were highlighted in a study performed by our group
investigating RHD variants in a donor population of 2027 apparently
RhD negative individuals. While this study detected 171 RHD positive
donors carrying a range of RHD variants, nine individuals carriedRHD al-
leles not deﬁned by genotyping on BloodChip Reference. RHD exon
scanning or Sanger sequencing was required to resolve these rare or
novel alleles [41]. An additional two samples remain unresolved follow-
ing Sanger sequencing, including sequencing of the untranslated and
putative cis-regulatory regions of the RHD gene [41]. Further investiga-
tion is continuing to deﬁne the RHD variants associated with the altered
RhD expression in these individuals.
3.5. Summary
In summary, SNVmicroarrays are a useful molecular tool for the de-
termination of blood group genotype. However, difﬁculty in resolution
of a case following microarray analysis can occur due to the presence
of a novel allele, a rare allele not incorporated in the microarray, or a
complex genetic variant, and further investigation must be performed.
If the gene causing the unresolved genotype is suspected then Sanger
sequencing offers an approach for resolution. The cases presented
here exemplify our laboratory's experience that up to 5–10% of complex
serological cases cannot be resolved by microarray genotyping and 1–
2% of these cases remain unresolved even after analysis by Sanger
sequencing.
4. Massively parallel sequencing to deﬁne a blood group phenotype
4.1. Overview of technology
MPS is emerging as themolecularmethod of choice in complex cases
which remain unresolved following traditional molecular investiga-
tions. Multiple MPS platforms have become commercially available
since the release of MPS in 2005 [42]. Although chemistry varies be-
tween platforms, in general MPS technologies start with a template li-
brary preparation step which involves fragmentation of DNA. The DNA
fragments are then ligated to adapters and read in parallel during DNA
synthesis to generate data up to the entire genome. Reads are then
mapped to a reference sequence, or assembled de novo, and variants
identiﬁed.
4.2. Advantages
Genotyping blood group SNVs using MPS technology has many ad-
vantages over serological phenotyping and other molecular methods
including in-house PCR-based tests, SNV microarrays and Sanger se-
quencing. A major advantage of MPS over SNV-based genotyping is
the applicability of MPS in detection of unknown polymorphisms. This
contrasts with SNV-based genotyping assays which only genotype in-
corporated SNVs and from Sanger sequencing in which each exonwith-
in a gene of interest must be individually sequenced. Additionally, MPS
has the potential to offer greater throughput than traditional methods,
once optimisation of protocols has been achieved. Another major ad-
vantage of MPS is the massive quantity of information obtained in one
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or exome.
4.3. Limitations
The major limitation of MPS technology is the challenge presented
by the substantial quantity of data generated and the associated infor-
mation technology requirements, including the management of bioin-
formatics analysis processes and data storage (space and security). In
addition, the cost of MPS remains high, though decreasing, and the
time-to-result is days to weeks, though also decreasing due to increases
in automation and optimisation of workﬂow and analysis. Optimisation
of bioinformatics tools and secure storage spaces to allow effective anal-
ysis of MPS data will be essential to the future development of MPS ap-
plications. Another important consideration is the detection of SNVs of
unknown signiﬁcance, as unlike targeted microarray approaches, the
whole sequence is obtained and variants with an unknown effect on
blood group antigen presentation may be detected.
Furthermore, ethical implications relevant to MPS must be consid-
ered. For example, if the purpose of MPS is to predict blood group anti-
gens then steps must be taken to ensure that non-relevant information
is appropriately managed. There are numerous ways this can be
achieved, dependent on the MPS approach utilized, for example, only
performing MPS on a selected panel of genes or amplicons, or not
performing sequence alignment or analysis of non-relevant genes.
Once data has been obtained, safeguards must be implemented to en-
sure donor and patient conﬁdentiality.
4.4. Applications
Three basic approaches can be utilized for an MPS investigation;
whole genome, whole exome or targeted gene sequencing. In the trans-
fusionmedicineﬁeld thewhole exome approach has shown value in re-
solving the genetic basis of “orphan” antigens. Cvejic et al. recently
applied MPS to resolve the genetic basis of Vel, a clinically signiﬁcant
high-frequency blood group antigen [43]. Exome sequencing of ﬁve un-
related Vel negative individuals identiﬁed the genetic basis of Vel and
provided evidence for the establishment of the Vel blood group system
[43]. Our group recently utilized MPS to resolve the genetic basis of the
low-frequency orphan antigen SARAH (SARA). SARA was discovered in
an Australian family in 1990 and has since been described in a Canadian
family where SARA incompatibility caused a severe case of Hemolytic
Disease of the Fetus and Newborn [44,45]. Our study involved exome
sequencing the SARA proband and family [46]. Collecting multiple
SARA positive and SARA negative samples from related individuals
was vital to the bioinformatics approach as exome sequencing identi-
ﬁed a total of approximately 500,000 SNVs [46]. The appropriate SNVﬁl-
tering steps are dependent on the case. In our study we excluded the
previously reported SNVs, non-protein coding SNVs and SNVs not
present in all SARA positive individuals and absent in all SARA negative
individuals. Following the identiﬁcation of the SARA SNV, G240T on
GYPA, we conﬁrmed our ﬁndings by performing Sanger sequencing of
the candidate gene (GenBank accession number KF973190).
Application of a targeted MPS approach was ﬁrst undertaken by
Stabentheiner et al. whoprovided proof of principal forMPS genotyping
of RHD variants [47]. More recently in research studies, MPS has
targeted selected panels of two to 18 blood group genes [48–50]. This
is an approach likely to increase in utilization as cost continues to
decrease. Over the next few years many laboratories will no doubt be
developing MPS assays targeting a full panel of blood group genes.
4.5. Summary
In summary, the genetic basis of blood group antigens can be com-
plex. MPS offers a new approach in cases which remain unresolved fol-
lowing traditional investigations including microarray analysis andSanger sequencing. Although MPS offers advantages over other
methods, including high-throughput capacity, there are limitations
and challenges to this approach which require further optimisation
before wide-spread adoption in the routine setting.
5. Summary and outlook
Molecular methods designed to predict clinically signiﬁcant blood
group antigens are a useful adjunct to overcoming the limitations of se-
rology and to ensure transfusion safety. From a clinical perspective, the
molecular methodwith themost utility is dependent on the complexity
of the case. For the majority of cases, genotyping by SNVmicroarray of-
fers a useful approach for the prediction of blood group antigen pheno-
type and offers advantages such as automated data analysis. A small
number of cases remain unresolved following genotyping by SNV mi-
croarray andmany of these cases can be resolved by Sanger sequencing.
The emergence of MPS is providing an approach to investigate complex
cases which remain unresolved. The major beneﬁts of MPS are the ca-
pacity to resolve rare and novel variants and the potential for high-
throughput testing. At present, on the research front, MPS approaches
are being applied to resolve the genetic basis of red blood cell orphan
antigens. In the future, routine blood group genotyping by SNVmicroar-
rays may be replaced by MPS approaches, however at this time, the re-
quirement for information technology resources remain too extensive
for routine use. Regardless of the molecular method used, the determi-
nation of a full proﬁle of blood group SNVs, in additional to serological
phenotyping, provides a basis for provision of compatible blood thus of-
fering improved transfusion safety.
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